Pre-earnings options volume in Summit Therapeutics (SMMT) is 2.8x normal with calls leading puts 19:3. Implied volatility suggests the market is anticipating a move near 6.1%, or 97c, after results are released. Median move over the past eight quarters is 13.8%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- SMMT Upcoming Earnings Report: What to Expect?
- Summit Therapeutics: Ivonescimab’s De-Risked Regulatory Path and Multi-Indication Upside Support $40 Target and Buy Rating
- Summit Therapeutics’ Ivonescimab BLA Accepted by FDA
- Summit Therapeutics announces FDA acceptance for filing of ivonescimab BLA
- Crescent Biopharma initiated with a Buy at Guggenheim